X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs STRIDES SHASUN LTD - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD STRIDES SHASUN LTD LUPIN LTD/
STRIDES SHASUN LTD
 
P/E (TTM) x 27.0 38.2 70.6% View Chart
P/BV x 2.8 1.0 297.1% View Chart
Dividend Yield % 0.6 1.0 56.5%  

Financials

 LUPIN LTD   STRIDES SHASUN LTD
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
STRIDES SHASUN LTD
Mar-17
LUPIN LTD/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,4651,275 114.9%   
Low Rs727918 79.2%   
Sales per share (Unadj.) Rs349.6389.6 89.7%  
Earnings per share (Unadj.) Rs5.628.0 19.9%  
Cash flow per share (Unadj.) Rs29.648.9 60.5%  
Dividends per share (Unadj.) Rs5.004.50 111.1%  
Dividend yield (eoy) %0.50.4 111.1%  
Book value per share (Unadj.) Rs300.3303.1 99.1%  
Shares outstanding (eoy) m452.0889.42 505.6%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x3.12.8 111.4%   
Avg P/E ratio x197.239.2 503.1%  
P/CF ratio (eoy) x37.122.4 165.3%  
Price / Book Value ratio x3.63.6 100.9%  
Dividend payout %90.016.1 559.1%   
Avg Mkt Cap Rs m495,50298,036 505.4%   
No. of employees `00017.05.8 293.8%   
Total wages/salary Rs m28,6475,881 487.1%   
Avg. sales/employee Rs Th9,273.66,005.9 154.4%   
Avg. wages/employee Rs Th1,681.01,014.0 165.8%   
Avg. net profit/employee Rs Th147.4431.2 34.2%   
INCOME DATA
Net Sales Rs m158,04234,834 453.7%  
Other income Rs m1,5041,686 89.2%   
Total revenues Rs m159,54536,520 436.9%   
Gross profit Rs m31,4756,428 489.7%  
Depreciation Rs m10,8591,872 580.2%   
Interest Rs m2,0442,269 90.0%   
Profit before tax Rs m20,0763,973 505.3%   
Minority Interest Rs m-710-   
Prior Period Items Rs m354 977.8%   
Extraordinary Inc (Exp) Rs m-14,644-1,006 1,456.1%   
Tax Rs m2,885470 613.7%   
Profit after tax Rs m2,5132,501 100.5%  
Gross profit margin %19.918.5 107.9%  
Effective tax rate %14.411.8 121.5%   
Net profit margin %1.67.2 22.1%  
BALANCE SHEET DATA
Current assets Rs m122,09538,165 319.9%   
Current liabilities Rs m50,95630,402 167.6%   
Net working cap to sales %45.022.3 202.0%  
Current ratio x2.41.3 190.9%  
Inventory Days Days8577 109.4%  
Debtors Days Days120104 114.8%  
Net fixed assets Rs m129,87637,639 345.1%   
Share capital Rs m904894 101.1%   
"Free" reserves Rs m134,86626,210 514.6%   
Net worth Rs m135,77127,105 500.9%   
Long term debt Rs m64,24516,377 392.3%   
Total assets Rs m263,05481,168 324.1%  
Interest coverage x10.82.8 393.5%   
Debt to equity ratio x0.50.6 78.3%  
Sales to assets ratio x0.60.4 140.0%   
Return on assets %1.75.9 29.5%  
Return on equity %1.99.2 20.1%  
Return on capital %3.712.1 30.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14113,465 394.7%   
Fx outflow Rs m19,3354,076 474.4%   
Net fx Rs m33,8079,389 360.1%   
CASH FLOW
From Operations Rs m17,5122,881 607.8%  
From Investments Rs m-14,073-7,051 199.6%  
From Financial Activity Rs m-14,9213,382 -441.2%  
Net Cashflow Rs m-11,482-788 1,457.9%  

Share Holding

Indian Promoters % 46.6 27.7 168.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 37.8 29.9%  
FIIs % 31.9 8.6 370.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 25.9 39.0%  
Shareholders   98,259 56,241 174.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   UNICHEM LAB  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets End Lower; Metal Stocks Top Losers(Closing)

Indian share markets settled lower today led by a fall in the financial stocks after the rupee hit a record low of 70.32 per dollar.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 16, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - ORCHID PHARMA LTD COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS